Lyndsay N Harris

发表

Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data

Xuegong Zhang, Qian Shi, Wing H Wong, 2006, BMC Bioinformatics.

Long‐term outcomes and clinicopathologic differences of African‐American versus white patients treated with breast conservation therapy for early‐stage breast cancer

Lyndsay N Harris, Qifeng Yang, L. Harris, 2008, Cancer.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Lyndsay N Harris, L. Harris, S. Shak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating next generation sequencing to practice: Opportunities and necessary steps

David Tuck, Vinay Varadan, Nevenka Dimitrova, 2013, Molecular oncology.

A role for the scaffolding adapter GAB2 in breast cancer

Andrea Richardson, Lyndsay N Harris, A. Richardson, 2006, Nature Medicine.

Requirement for CDK4 kinase function in breast cancer.

Yan Geng, Olle Stål, Lyndsay N Harris, 2006, Cancer cell.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

David L Rimm, Natalie Sinclair, Yalai Bai, 2014, BMC Cancer.

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Andre T Baron, Murli Narayan, Lyndsay N Harris, 2009, Cancer research.

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Donald Berry, Lyndsay N Harris, Lynn Dressler, 2006, Breast Cancer Research.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

David Tuck, Vinay Varadan, Hannah Gilmore, 2016, Clinical Cancer Research.

Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery.

Robert Gentleman, Xin Lu, Justin Hwang, 2006, Journal of proteome research.

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Jerry Younger, Lyndsay N Harris, Judy E Garber, 2008, Clinical Cancer Research.

Triple negative breast cancer: current understanding of biology and treatment options

Lyndsay N Harris, L. Harris, M. Martel, 2008, Current opinion in obstetrics & gynecology.